Analysis of the clinical problems in parkinsonism and the complications of long‐term levodopa therapy

We evaluated the current status of 131 patients with idiopathic parkinsonism who were receiving levodopa therapy. The residual parkinsonian symptoms and signs were tabulated, as were the adverse effects from medication. Response to therapy was correlated with duration of the disease and with duration of treatment. Patients with on-off or wearing-off effects were likely to have been treated for 4 years or longer. Patients treated with levodopa for 4 to 8 years were significantly more impaired with parkinsonism than patients treated for 0 to 3 years, even when patients were matched for total duration of disease. These data suggest that the deterioration of responsiveness after several years of levodopa therapy may be due to the therapy itself. Our findings support the concept that utilization of levodopa therapy should be delayed until a patient becomes significantly impaired in occupational or social situations.

[1]  G C Cotzias,et al.  Modification of Parkinsonism--chronic treatment with L-dopa. , 1969, The New England journal of medicine.

[2]  W. Bowman ENCEPHALITIS AND PARKINSONISM. , 1965, JAMA.

[3]  C. Marsden,et al.  SUCCESS AND PROBLEMS OF LONG-TERM LEVODOPA THERAPY IN PARKINSON'S DISEASE , 1977, The Lancet.

[4]  C. Joseph,et al.  Levodopa in Parkinson disease: A long‐term appraisal of mortality , 1978, Annals of neurology.

[5]  M. Muenter,et al.  L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. , 1971, Mayo Clinic proceedings.

[6]  R. Duvoisin,et al.  Response of patients with postencephalitic Parkinsonism to levodopa 1 , 1972, Journal of neurology, neurosurgery, and psychiatry.

[7]  A. Koeppen,et al.  Striatonigral degeneration , 2004, Acta Neuropathologica.

[8]  F. Mcdowell,et al.  Intellectual impairment in Parkinson's syndrome. , 1972, Brain : a journal of neurology.

[9]  A. Barbeau L-dopa therapy in Parkinson's disease: a critical review of nine years' experience. , 1969, Canadian Medical Association journal.

[10]  T. Sourkes,et al.  Effect of amine precursors on the concentration of striatal dopamine and serotonin in cats with and without unilateral brain stem lesions. , 1967, Brain research.

[11]  Z. Schwab,et al.  Projection technique for evaluating surgery in Parkinson’s disease , 1969 .

[12]  W. Weiner,et al.  Recent advances in the biochemical pharmacology of extrapyramidal movement disorders. , 1977, Advances in experimental medicine and biology.

[13]  D. Laplane,et al.  [Treatment of Parkinson's disease with bromocriptine]. , 1976, La Nouvelle presse medicale.

[14]  D. Laurence,et al.  Sustained levodopa therapy in parkinsonism. , 1973, Lancet.

[15]  R. Duvoisin,et al.  Treatment of parkinsonism with levodopa. , 1969, Archives of neurology.

[16]  S. Fahn “On‐off” phenomenon with levodopa therapy in parkinsonism , 1974, Neurology.

[17]  L. Schiffer,et al.  Aromatic amino acids and modification of parkinsonism. , 1967, The New England journal of medicine.

[18]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[19]  W. E. Martin,et al.  Patterns of clinical response and plasma dopa levels in Parkinson's disease , 1975, Neurology.

[20]  S. Fahn,et al.  Considerations in the management of parkinsonism , 1978, Neurology.

[21]  V. Tennyson,et al.  5-Hydroxydopamine 'tagged' neuronal boutons in rabbit neostriatum: interrelationship between vesicles and axonal membrane. , 1974, Brain research.

[22]  N. Krasner,et al.  L-dopa for postencephalitic Parkinsonism. , 1970, British medical journal.